ClearMind Biomedical’s novel neurosurgical endoscope, the Axonpen System, has completed its First in Man (FIM) clinical trial in Taiwan with outstanding results. The Axonpen System which received US FDA 510(k) clearance in 2020 and from the Taiwan FDA in 2021, is designed to enable neurosurgeons worldwide to perform the least invasive brain surgeries for their patients. With the device requiring only a 6.5mm channel to access the intracranial space, the Axonpen System has broken ground as the least invasive treatment...